MICM
TERN

Matthews International Capital Management’s Terns Pharmaceuticals TERN Stock Holding History

Matthews International Capital Management’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-875,068
Closed -$9.12M – 44
2021
Q3 		$9.12M Sell
875,068
-196,353
-18% -$2.04M 0.55% 25
2021
Q2 		$13.1M Hold
1,071,421
– – 0.55% 27
2021
Q1 		$23.6M Buy
+1,071,421
New +$23.5M 0.98% 25

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Matthews International Capital Management's TERN Position: Q4 2021 in Review

Matthews International Capital Management sold out of Terns Pharmaceuticals (TERN) in Q4 2021, closing a stake of 875,068 shares — an estimated $9.12M sold.

Matthews International Capital Management first reported a position in TERN in Q1 2021 and held it in 3 quarters. The position peaked at $23.6M in Q1 2021. 37 funds tracked by Wall St. Rank hold TERN as of Q4 2021.

  • Matthews International Capital Management reported no remaining Terns Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • Matthews International Capital Management sold 875,068 Terns Pharmaceuticals shares in Q4 2021, an estimated $9.12M.
  • Matthews International Capital Management first reported a position in Terns Pharmaceuticals in Q1 2021 and held it in 3 quarters.
  • Matthews International Capital Management's Terns Pharmaceuticals position peaked at $23.6M in Q1 2021.
  • 37 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2021.

Based on Matthews International Capital Management's 13F filing for Q4 2021, filed 2 Feb 2022.